|
| Press Releases |
|
 |
|
| Wednesday, May 31, 2017 |
|
|
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine |
| Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new antimalarial medicine based on antimalarial drug targets the team identified last year. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate and eribulin mesylate, as well as H3B-8800 will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). more info >> |
|
| Wednesday, April 19, 2017 |
|
|
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis |
| Eisai Co., Ltd. has announced the results of its initiatives for the elimination of lymphatic filariasis (LF), and its continued support of this cause in the future. more info >> |
|
| Tuesday, April 11, 2017 |
|
|
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series |
| Eisai Co., Ltd. announced today that, approaching the 65th anniversary of its Chocola BB brand, it will launch Chocola BB Gold Rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on Monday, April 17. more info >> |
|
| Wednesday, April 5, 2017 |
|
|
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson's Disease Drug Safinamide in Japan and Asia |
| Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced today that they have entered into a license agreement for the commercialization of safinamide for the treatment of Parkinson's disease in Japan and Asia. Safinamide is currently under clinical development by Meiji in Japan. more info >> |
|
|
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting |
| Eisai Co., Ltd. announced today that it has presented the latest research data regarding a mechanism of action that led to increased anti-tumor activity in mouse models which had been dosed with a combination of the in-house developed anticancer agent lenvatinib mesylate and an anti-mouse PD-1 antibody, at the AACR 108th Annual Meeting. more info >> |
|
| Tuesday, April 4, 2017 |
|
|
Eisai to Launch Smell Identification Test UPSIT Series in Japan |
| Eisai Co., Ltd. has announced that the smell identification test "UPSIT Series" will be launched today for sale to health insurance pharmacies and local governments in Japan. more info >> |
|
| Wednesday, March 29, 2017 |
|
|
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan |
| Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat in patients with early Alzheimer's disease (AD). more info >> |
|
|
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house developed anticancer agent Kisplyx (lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma (RCC) compared to everolimus alone in its assessment for insurance reimbursement. more info >> |
|
| Wednesday, January 25, 2017 |
|
|
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint |
| Eisai Co., Ltd. announced today that a Phase III clinical trial of its in-house discovered and developed anticancer agent Lenvima against the comparator sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma has achieved its primary endpoint. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TANAKA PRECIOUS METAL TECHNOLOGIES, 5세대 신호 릴레이용 차세대 접점 ‘극소형 크로스바 접점’ 개발
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES開發出適用於第5代訊號繼電器的次世代接點「極小CROSS BAR接點（帶狀接點）」
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES已开发了面向第5代信号继电器的次世代接点 “微小CROSS BAR接点（异型材带状接点）”
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Develops Miniaturized Micro Profile, a Next-Generation Contact tape for Fifth-Generation Signal Relays
Mar 12, 2025 11:00 JST
|
|
|
JCB Now Available on Google Play in Thailand, Indonesia, Vietnam, Philippines, and Hong Kong
Mar 12, 2025 11:00 JST
|
|
|
Bear Robotics「Carti 100」榮獲 2025 年 iF 設計大獎，引領物流自動化新標準
Mar 11, 2025 23:58 HKT/SGT
|
|
|
Bear Robotics' Carti 100 Wins iF DESIGN AWARD 2025, Setting New Standards in Logistics Automation
Mar 11, 2025 23:58 HKT/SGT
|
|
|
Formerra Introduces Formerra+ Upgraded Ecommerce Site to Optimize Customer Experience
Mar 11, 2025 22:15 HKT/SGT
|
|
|
135 Years of Sport Inspiration: U.S. Polo Assn. Hosts Celebration Cup Exhibition and Spring-Summer 2025 Fashion Showcase in Delhi
Mar 11, 2025 20:00 HKT/SGT
|
|
|
聯想控股旗下君聯資本、正奇能科集團共同投資企業漢朔科技在深交所成功上市
Mar 11, 2025 19:00 HKT/SGT
|
|
|
联想控股旗下君联资本、正奇能科集团共同投资企业汉朔科技在深交所成功上市
Mar 11, 2025 18:52 HKT/SGT
|
|
|
2024 Results of Qunabox Group Released: Leading AI Interactive Marketing with Strong Revenue and Profit Growth
Mar 11, 2025 18:50: JST
|
|
|
2024 Results of Qunabox Group Released: Leading AI Interactive Marketing with Strong Revenue and Profit Growth
Mar 11, 2025 17:50 HKT/SGT
|
|
|
JCB Announced Premier Sponsorship for the 10th Edition of Sakura 2025 at Singapore's Gardens by the Bay
Mar 11, 2025 18:00 JST
|
|
|
Hitachi Energy invests additional $250 million USD to address global transformer shortage
Mar 11, 2025 17:49 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
